Skip to main content
NEWLAND PHARMACEUTICAL CO., LTD logo

NEWLAND PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 301277 ISIN · CNE1000065K2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2023-06-08 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 301277

About NEWLAND PHARMACEUTICAL CO., LTD

https://www.newlandpharma.com

Newland Pharmaceutical Co., Ltd. is a specialized enterprise engaged in the research, development, manufacturing, and global distribution of active pharmaceutical ingredients (APIs) and high-quality chemical intermediates. The company focuses on a broad spectrum of therapeutic categories, including cardiovascular, anti-infective, and metabolic health solutions. Operating with a commitment to rigorous quality control, its production facilities are designed to meet international Good Manufacturing Practice (GMP) standards. Newland Pharmaceutical prioritizes technological innovation and chemical synthesis optimization to deliver reliable pharmaceutical components. Its core operations involve the large-scale production of complex molecules, supporting the supply chains of healthcare providers and pharmaceutical formulators worldwide through a focus on technical excellence and regulatory compliance.

Recent filings

Filing Released Lang Actions
北京市天元律师事务所关于河南新天地药业股份有限公司2023年第二次临时股东大会的法律意见
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the procedures, qualifications, and voting results of a company's 2023 second extraordinary general meeting (临时股东大会). It details the convening, attendance, voting procedures, and results of shareholder resolutions. The document is not a financial report, earnings release, or management discussion, but rather a formal legal opinion on the validity and legality of the shareholder meeting and its outcomes. This type of document is typically classified under Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results of a shareholder meeting.
2023-06-08 Chinese
关于使用部分闲置募集资金购买结构性存款到期赎回并继续购买结构性存款的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 河南新天地药业股份有限公司 regarding the use of part of idle raised funds to purchase structured deposits and the redemption and continued purchase of such deposits. It details amounts, banks, product types, expected yields, and risk control measures. The document is a formal announcement about the company's cash management activities involving idle raised funds, including approvals by the board and supervisory committees. It does not contain financial statements, quarterly or annual results, nor is it a report or transcript. It is not a certification or a short note about report publication. The content fits the category of Capital/Financing Update (CAP), as it relates to the company's management of capital raised and investment of idle funds in financial products.
2023-06-08 Chinese
华泰联合证券有限责任公司关于河南新天地药业股份有限公司使用超募资金投资建设新项目的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from the sponsor institution (华泰联合证券有限责任公司) regarding the use of excess raised funds by 河南新天地药业股份有限公司 for investing in a new project. It includes detailed information about the fundraising, usage plans, project description, investment necessity and feasibility, risk analysis, and approval procedures by the board, supervisory committee, and independent directors. The document is regulatory in nature, focusing on compliance with fundraising usage rules and approvals, but it is not a financial report, earnings release, or a direct announcement of voting results. It is a formal verification and opinion report related to capital usage and fundraising compliance, which fits best under the category of Capital/Financing Update (CAP). The document length is substantial (9049 characters), and it contains substantive content rather than just an announcement or certification, so it is not RPA or RNS. Therefore, the most appropriate classification is CAP with high confidence.
2023-05-23 Chinese
关于拟变更公司名称的公告
Board/Management Information Classification · 95% confidence The document is an announcement from Henan Newland Pharmaceutical Co., Ltd. regarding a proposed change in the company's name. It includes details about the board meeting resolution, the rationale for the name change, and the need for shareholder approval. There are no financial statements, earnings data, or detailed financial analysis present. The document is a formal corporate announcement about a board decision and upcoming shareholder vote on a corporate governance matter (company name change). This fits best under Board/Management Information (MANG) as it relates to a significant corporate governance change approved by the board and pending shareholder approval. The document length is short and it is not a report or financial filing but an announcement of a board decision.
2023-05-23 Chinese
关于召开2023年第二次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed notice about convening the 2023 second extraordinary general meeting of shareholders for 河南新天地药业股份有限公司. It includes information about the meeting date, voting procedures (both onsite and online), agenda items to be voted on, registration details, and proxy forms. There is no financial data or results reported, nor is it a transcript or presentation. It is a formal announcement inviting shareholders to attend and vote on specific proposals. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which provides materials sent to shareholders to inform and request votes for meetings.
2023-05-23 Chinese
独立董事关于对第五届董事会第十三次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors regarding matters discussed at the 13th meeting of the 5th Board of Directors of Henan Xintiandi Pharmaceutical Co., Ltd. It discusses approval of proposals such as the change of company name and use of over-raised funds for investment projects. The document references compliance with company law and regulatory guidelines but does not contain financial statements or detailed financial data. It is a formal board-related opinion document rather than a full annual report, audit report, or financial report. It is not a simple announcement or certification but a management/board opinion on corporate governance matters. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on board meeting opinions, not a full report or announcement of a report.
2023-05-23 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.